Are you Dr. Entmacher?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
175 Madison Ave
# 4
Westampton, NJ 08060Phone+1 609-702-1900Fax+1 609-702-8455
Summary
- Dr. Michael Entmacher, MD is an oncologist in Westampton, New Jersey. He is currently licensed to practice medicine in New Jersey. He is affiliated with Virtua Mount Holly Hospital and Virtua Voorhees.
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1974 - 1975
- Duke University HospitalResidency, Internal Medicine, 1973 - 1974
- Ohio State University HospitalResidency, Internal Medicine, 1970 - 1971
- Duke University HospitalInternship, Internal Medicine, 1969 - 1970
- Duke University School of MedicineClass of 1969
Certifications & Licensure
- NJ State Medical License 1984 - 2015
Awards, Honors, & Recognition
- Inside Jersey Top Doctors for Cancer Castle Connolly, 2014
- Inside Jersey Magazine Top Doctors Castle Connolly, 2012-2014
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
- Join now to see all
Publications & Presentations
PubMed
- 22 citationsPhase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.Naomi B. Haas, Bruce J. Roth, Carlos Garay, Gwen Yeslow, Michael Entmacher
Urology. 2001-07-01 - 161 citationsVinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Ph...Gary R. Hudes, Lawrence H. Einhorn, Eric Ross, Andrew Balsham, Patrick J. Loehrer
Journal of Clinical Oncology. 1999-10-01
Professional Memberships
- Member
- Member